Results 751 - 775 of 1095

This 13-page bibliography lists MSH-authored publications on aspects of HIV/AIDS. It includes 93 peer-reviewed journal articles led by or with MSH authors, as well as MSH publications (technical briefs, position papers, and issues of The Manager) and selected major project reports. The bibliography was updated in January 2017.

INSIDE STORY tells the story of Kalu, a rising Kenyan footballer, who moves from rural Kenya to urban Johannesburg to follow his dream and support his family. His path becomes more challenging when he falls in love with the coach’s daughter Ify and subsequently finds out he is HIV-positive.

PROGRES is a master organizational capacity assessment tool developed by Management Sciences for Health (MSH) staff in February 2014.

In recent years, Democratic Republic of the Congo (DRC) has increasingly focused on strengthening its health system and improving health outcomes for its 79.8 million people.

Performance-based financing (PBF) has been used increasingly to improve the quantity and quality of health services by directly rewarding providers with financial incentives based on achieved results.

Management Sciences for Health (MSH) has been assisting Malawi since 2003 to strengthen health care systems, increase disease prevention education, reduce maternal and childhood mortality rates, and expand access to quality HIV/AIDS services.

Users of e-TB Manager, a web-based eHealth system institutionalized in 10 resource-constrained countries that account for one-third of the world’s tuberculosis (TB) burden, reported that e-TB Manager helped to improve patient care and workplace productivity, and they found it reliable for case management. The users--especially those with more experience in TB programs and those who had used the system for more than two years--were generally satisfied with the system. Responses came from Armenia, Bangladesh, Brazil, Cambodia, Namibia, Nigeria, Indonesia, Ukraine, and Vietnam. The study concluded that younger users and those with less experience in TB programs need more training, and institutional capacity for managing e-TB Manager takes at least five years. The capacity  to manage e-TB Manager has been built in Brazil and Ukraine.

This selected bibliography of MSH publications and tools on health economics and health care financing covers the period 2000-2016. It demonstrates MSH's strengths in performance-based financing, universal health care, insurance, costing of health services, and capacity building in financial management, among other areas.

We examined how different training modalities have been employed and adapted in 12 countries to meet country-specific needs by a global pharmaceutical systems strengthening program in collaboration with a country’s Ministry of Health and local stakeholders. Case-based learning, practice and feedback, and repetitive interventions such as post-training action plan, supportive supervision and mentoring approaches are effective, evidence-based training techniques. In Ethiopia and Bangladesh, over 94% of respondents indicated that they have improved or developed skills or competencies as a result of the program’s training activities. Supportive supervision structures and mentorship have been institutionalized with appropriate management structures. National authorities have been sensitized to secure funding from domestic resources or from Global Fund grants for post-training follow-up initiatives. The Pharmaceutical Leadership Development Program is an effective, case-based training modality that motivates staff to develop quality-improvement interventions and solve specific challenges. Peer-to-peer learning mechanisms rather than traditional didactic methods was a preferred intervention among high level government officials both within country and between countries.

This page provides instructions for upgrading or reinstalling the QuanTB software on Mac or PC. To learn more about QuanTB and download the software for Mac or PC, please visit the main QuanTB page.

This page provides a technical brief for the QuanTB software.

This page provides the QuanTB User's Guide and Installation Instructions. To learn more about QuanTB and download the software for Mac or PC, please visit the main QuanTB page.

From community health workers in Haiti, to drug shop owners in eastern Tanzania, to midwives in western Afghanistan, the impact of Management Sciences for Health (MSH) has been felt throughout the developing world.

Year Ended June 30, 2016, drawn from audited financial statements.

MSH’s 45 years of history demonstrate that long-term investments in health systems strengthening and capacity building can result in sustainable improvements in health, saving lives of the most vulnerable people. MSH continues to strengthen health systems and facilitate innovations that save lives and improve health for all.

Private-sector retail drug outlets are often the first point of contact for common health ailments, including tuberculosis (TB). The objective of this systematic review was to better understand the extent to which the World Health Organization’s (WHO) recommendation on engaging retail drug outlets has been translated into programmatic policy, strategy, and intervention in low- and middle-income countries. The study found that of national strategic plans for TB control from 14 countries with varying TB burdens and a strong private sector, only 2 had explicit statements on the need to engage their national pharmacy professional association. The success rate of referrals from retail drug outlets who visited an approved health facility for TB screening ranged from 48% in Vietnam to 86% in Myanmar. Coverage of retail drug outlets ranged from less than 5 to 9% of the universe of retail drug outlets. For WHO’s End TB Strategy to be successful, scaling up retail drug outlets to increase national coverage, at least in countries with a thriving private sector, will be instrumental in accelerating the early detection and referral of the 3 million missing TB cases. The proposed public-private mix pharmacy model is applicable not only for TB control but also to tackle the antimicrobial resistance crisis in these countries.

High-quality, patient-centered antenatal care (ANC) is a key strategy for improving maternal and newborn health and a critical component in the continuum of care.

Ukraine has successfully implemented e-TB Manager nationwide as its mandatory national tuberculosis registry after first introducing it in 2009. Our objective was to perform an end-of-programme evaluation after formal handover of the registry administration to Ukraine's Centre for Disease Control in 2015. Of the 5.9 million transactions over a 4-year period, nine out of 24 oblasts (regions) and Kiev City accounted for 62.5% of all transactions, and corresponded to 59% of Ukraine's tuberculosis burden. There were 437 unique active users in 486 rayons (districts) of Ukraine, demonstrating extensive reach.

One of the key elements of successful tuberculosis (TB) control programs is adherence to treatment, which is a cornerstone of most international and national policies and guidelines. Non- adherence results in increased length and severity of illness, death, disease transmission, and drug resistance.

Malaria accounts for the largest portion of healthcare demand in Angola. Cross-sectional health facility surveys were performed in low-transmission Huambo and high-transmission Uíge Provinces in early 2016. In each province, 45 health facilities were randomly selected from among all public health facilities stratified by level of care. The results reveal important diferences between provinces. Despite similar availability of testing and ACT, testing and treatment rates were lower in Huambo compared to Uíge. A majority of true malaria cases seeking care in health facilities in Huambo were not appropriately treated with anti-malarials, highlighting the importance of continued training and supervision of healthcare workers in malaria case management, particularly in areas with decreased malaria transmission.

Tuberculosis (TB) is a major public health problem in Afghanistan, but experience in implementing effective strategies to prevent and control TB in urban areas and conflict zones is limited. This study shares programmatic experience in implementing DOTS in the large city of Kabul. We analyzed data from the 2009–2015 reports of the National TB Program (NTP) for Kabul City and calculated treatment outcomes and progress in case notification. Between 2009 and 2015, the number of DOTS-providing centers in Kabul increased from 22 to 85. In total, 24,619 TB patients were enrolled in TB treatment during this period. The case notification rate for all forms of TB increased from 59 per 100,000 population to 125 per 100,000. The case notification rate per 100,000 population for sputum-smear-positive TB increased from 25 to 33. The treatment success rate for all forms of TB increased from 31% to 67% and from 47% to 77% for sputum-smear-positive TB cases. In 2013, contact screening was introduced, and the TB yield was 723 per 100,000—more than two times higher than the estimated national prevalence of 340 per 100,000. Contact screening contributed to identifying 2,509 child contacts of people with TB, and 76% of those children received isoniazid preventive therapy. The comprehensive urban DOTS program significantly improved service accessibility, TB case finding, and treatment outcomes in Kabul. Public- and private-sector involvement also improved treatment outcomes; however, the treatment success rate remains higher in private health facilities. While the treatment success rate increased significantly, it remains lower than the national average, and more efforts are needed to improve treatment outcomes in Kabul. We recommend that the urban DOTS approach be replicated in other countries and cities in Afghanistan with settings similar to Kabul.

Vitamin D is a fat-soluble vitamin that increases immunity against tuberculosis (TB), decreases the re-activation of latent TB and reduces the severity of active TB disease. Epidemiological studies on the prevalence of vitamin D deficiency and its association with TB have shown inconsistent results in different countries. This study aimed to determine the prevalence of vitamin D deficiency and its association with TB in Northwest Ethiopia. A case–control study was conducted among smear positive pulmonary TB patients and their household contacts without symptoms suggestive of TB. Study participants were recruited at 11 TB diagnostic health facilities in North and South Gondar zones of Amhara region between May 2013 and April 2015. Vitamin D deficiency is highly prevalent among TB patients and non-TB controls in Ethiopia, where there is year-round abundant sunshine. Study participants with TB, females, older age groups, and urban residents had significantly higher prevalence of vitamin D deficiency. These findings warrant further studies to investigate the role of vitamin D supplementation in the prevention and treatment of TB in high TB burden countries like Ethiopia.

This article presents Malawi’s experience with designing and implementing Option B+ and provides complementary narratives from Cameroon and Tanzania. Operationalizing Option B+ required several critical considerations, including the complete integration of ART and PMTCT programs, systematic reduction of barriers to facilitate doubling the number of ART sites in less than a year, building consensus with stakeholders, and securing additional resources. During the planning and implementation process, several lessons were learned which are considerations for countries transitioning to “treat-all”: Comprehensive change requires effective government leadership and coordination; national clinical guidelines must accommodate health system limitations; ART services and commodities should be decentralized within facilities; the general public should be well informed about major changes in the national HIV program; and patients should be educated on clinic processes to improve program monitoring.

An extensive body of work on access to and use of medicines has resulted in an assortment of tools measuring various elements of pharmaceutical systems. Until now however, there has been little attempt to conceptualize a pharmaceutical system as an entity and define its strengthening in a way that allows for measuring systems strengthening. The narrow focus of available tools limits their value in ascertaining which interventions result in stronger, more resilient systems. We sought to address this shortcoming by revisiting the current definitions, frameworks and assessment tools related to pharmaceutical systems. We conducted a comprehensive literature review and consulted with select pharmaceutical experts. On the basis of our review, we propose that a pharmaceutical system consists of all structures, people, resources, processes, and their interactions within the broader health system that aim to ensure equitable and timely access to safe, effective, quality pharmaceutical products and related services that promote their appropriate and cost-effective use to improve health outcomes. We further propose that pharmaceutical systems strengthening is the process of identifying and implementing strategies and actions that achieve coordinated and sustainable improvements in the critical components of a pharmaceutical system to make it more responsive and resilient and to enhance its performance for achieving better health outcomes. Finally, we established that, in addition to system performance and resilience, seven components of the pharmaceutical system are critical for measuring pharmaceutical systems strengthening: pharmaceutical products and related services; policy, laws and governance; regulatory systems; innovation, research and development, manufacturing, and trade; financing; human resources; and information.

A cross-sectional qualitative study was conducted to explore early experiences surrounding "Option B+" for patients and health care workers in Malawi. As "Option B+" continues to be rolled out, novel interventions to support and retain women in care must be implemented. These include providing space, time, and support to accept a diagnosis before starting ART, engaging partners and families, and addressing the need for peer support and confidentiality.


Printer Friendly Version